Reviewing Brookline Capital Acquisition (NASDAQ:BCAC) and VectivBio (NASDAQ:VECT)

Brookline Capital Acquisition (NASDAQ:BCACGet Rating) and VectivBio (NASDAQ:VECTGet Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Earnings & Valuation

This table compares Brookline Capital Acquisition and VectivBio’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Brookline Capital Acquisition N/A N/A -$480,000.00 N/A N/A
VectivBio N/A N/A -$87.01 million N/A N/A

Profitability

This table compares Brookline Capital Acquisition and VectivBio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Brookline Capital Acquisition N/A -416.32% -4.75%
VectivBio N/A N/A N/A

Insider and Institutional Ownership

51.8% of Brookline Capital Acquisition shares are owned by institutional investors. 19.2% of Brookline Capital Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Brookline Capital Acquisition has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500. Comparatively, VectivBio has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Brookline Capital Acquisition and VectivBio, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brookline Capital Acquisition 0 0 0 0 N/A
VectivBio 0 0 2 0 3.00

VectivBio has a consensus target price of $26.50, indicating a potential upside of 223.17%. Given VectivBio’s higher probable upside, analysts clearly believe VectivBio is more favorable than Brookline Capital Acquisition.

About Brookline Capital Acquisition

(Get Rating)

Brookline Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to acquire companies in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.

About VectivBio

(Get Rating)

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Receive News & Ratings for Brookline Capital Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brookline Capital Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.